Aortic Stenosis Market Analysis, Size, Share & Growth Forecast 2026–2034

PARTNER 3 Low-Risk TAVI 8.5 Versus 15.1 Percent Death and Stroke Rate Significantly Better Than SAVR Has Established TAVI as the Preferred Treatment Across the Full Risk Spectrum for the Severe Aortic Stenosis Patient With the Suitable Transfemoral Access Anatomy.The PARTNER 3 and Evolut Low Risk trials demonstrated non-inferiority or superiority of TAVR versus SAVR in low-surgical-risk patients at two and five years for the primary composite of death, stroke, and rehospitalisation, triggering guideline updates that made TAVR the preferred treatment in anatomically suitable patients regardless of surgical risk. Edwards Lifesciences and Medtronic generate over USD 7 billion combined annually from TAVR systems, with balloon-expandable Sapien 3 Ultra and self-expanding Evolut FX competing for share in a market where technical refinements in delivery system profile, valve skirt design, and pacing rate reduction differentiate products on procedural metrics. The extension of TAVR to low-risk patients approximately doubled the addressable population from the intermediate and high-risk patients who received approval first, creating the commercially significant TAVR indication expansion.

Valve-in-Valve TAVI for Failed Surgical Bioprosthetic Valve Avoiding Re-Operative SAVR Risk From Sternotomy Reopening Has Provided the Transcatheter Re-Intervention That Extends the TAVI Technology to the 10 to 15-Year Post-SAVR Bioprosthesis Degeneration Patient.PARTNER 3 five-year data and Evolut Low Risk cohort analyses through 2025 provide the first long-term durability assessment for contemporary TAVR systems in lower-surgical-risk patients, with both trials showing comparable rates of structural valve deterioration to surgical bioprosthetic valves at equivalent follow-up. The key durability question for younger TAVR patients is whether TAVR valve durability at 15-20 years matches the 15-20 year durability of surgical bioprosthesis or whether TAVR patients will require redo TAVR-in-TAVR procedures that add procedural complexity and mortality risk. Leaflet thrombosis, a subclinical finding on 10-20% of surveillance CT scans that resolves with anticoagulation, has generated ongoing research into optimal TAVR antithrombotic regimens that prevent structural valve deterioration from thrombus-related calcification without adding bleeding risk.

Low-Profile 14 Fr Delivery System Enabling Femoral Access in Smaller Artery Diameter That 18 to 22 Fr Earlier Devices Excluded Has Expanded TAVI Anatomical Eligibility to the Patients Whose Peripheral Vascular Anatomy Previously Required the Alternative Transapical or Subclavian Approach.Self-expanding Evolut Pro+ and Evolut FX demonstrate lower rates of new permanent pacemaker implantation compared with first-generation self-expanding valves through redesigned annular contact geometry and enhanced implantation technique guidance, addressing the 15-25% pacing rate that was the primary clinical concern differentiating self-expanding from balloon-expandable TAVR. Balloon-expandable Sapien 3 Ultra's rigid annular contact provides more predictable paravalvular leak sealing in irregular calcified anatomy while requiring more precise sizing to avoid annular injury, establishing complementary anatomic preferences for each platform. Valve-in-valve TAVR for failed surgical bioprosthesis is the fastest-growing TAVR indication as the large wave of surgical valves implanted in the 1990s-2000s reach end of durability, creating a redo intervention market where each valve platform demonstrates distinct performance characteristics in the confined neolumen.

For related market intelligence, see the Cardiology Drug Market.